HIV Complicated with Talaromyces Marneffei Multisystem Infection: A Case Report and Literature Review
- PMID: 40718368
- PMCID: PMC12292354
- DOI: 10.2147/IDR.S534364
HIV Complicated with Talaromyces Marneffei Multisystem Infection: A Case Report and Literature Review
Abstract
HIV-infected individuals typically present with diverse clinical manifestations and heightened susceptibility to various opportunistic infections. We present a case of a hospitalized HIV patient presenting with dizziness, headache, and lip numbness. Neuroimaging revealed disseminated lesions involving bilateral cerebral hemispheres, spinal cord, pulmonary parenchyma, and mesenteric lymph nodes, subsequently confirmed through cerebrospinal fluid analysis and genetic testing as systemic TM infection. Following a 10-day course of intravenous amphotericin B, the patient demonstrated symptomatic improvement and was discharged. Post-discharge management included combination antiretroviral therapy (Bictegravir/Emtricitabine/Tenofovir alafenamide) with oral itraconazole prophylaxis. One-year follow-up imaging demonstrated near-complete resolution of systemic lesions. This report highlights characteristic radiological patterns and emphasizes the importance of considering disseminated TM infection in HIV patients with neurological involvement, particularly in endemic regions.
Keywords: CT; HIV; MRI; case report; multisystem infection; talaromyces marneffei.
© 2025 Zhang et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures





Similar articles
-
Identification of Talaromyces marneffei Infection in an HIV-Negative Patient by ITS Sequencing.Infect Drug Resist. 2023 Aug 14;16:5275-5282. doi: 10.2147/IDR.S418174. eCollection 2023. Infect Drug Resist. 2023. PMID: 37601563 Free PMC article.
-
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.Lancet HIV. 2025 Jul;12(7):e473-e484. doi: 10.1016/S2352-3018(25)00105-5. Epub 2025 Jun 7. Lancet HIV. 2025. PMID: 40489982 Clinical Trial.
-
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.Lancet HIV. 2024 May;11(5):e300-e308. doi: 10.1016/S2352-3018(23)00327-2. Epub 2024 Apr 12. Lancet HIV. 2024. PMID: 38621393 Clinical Trial.
-
Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002835. doi: 10.1002/14651858.CD002835.pub3. Cochrane Database Syst Rev. 2007. PMID: 17253483 Free PMC article.
-
Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003940. doi: 10.1002/14651858.CD003940.pub3. Cochrane Database Syst Rev. 2010. PMID: 21069679 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources